Pipeline powered by groundbreaking glyco targeting engine
GO Therapeutics’ platform is continually generating new solid tumor targets, feeding a growing pipeline of novel cancer immuno-therapies.
ANTIBODY PROGRAM
MODALITIES
INDICATIONS
Mucins
GO-2
TCB
Breast, Colon, Ovarian
ANTIBODY PROGRAM
GO-2
MODALITIES
TCB
INDICATIONS
Breast, Colon, Ovarian
GO-2D5
TCB
Pancreatic, CRC, Bile Duct, Breast, Ovarian
ANTIBODY PROGRAM
GO-2D5
MODALITIES
TCB
INDICATIONS
Pancreatic, CRC, Bile Duct, Breast, Ovarian
Receptor Proteins
GO-4C8
CAR-T
Colon, Head & Neck, Lung
ANTIBODY PROGRAM
GO-4C8
MODALITIES
CAR-T
INDICATIONS
Colon, Head & Neck, Lung
GO-14C9
TCB
Liver, Gastric, Esophageal, Colon
ANTIBODY PROGRAM
GO-14C9, GO-8H3
MODALITIES
CAR-T, TCB
INDICATIONS
Liver, Gastric, Esophageal, Colon
GO-8H3
CAR-T
GO-17A3
CAR-T, TCB
Sarcoma, Melanoma
ANTIBODY PROGRAM
GO-17A3
MODALITIES
CAR-T, TCB
INDICATIONS
Sarcoma, Melanoma
Lysomal
GO-3C7
ADC
Prostate, Uterus, Head & Neck, Adenocarcinoma
ANTIBODY PROGRAM
GO-3C7
MODALITIES
ADC
INDICATIONS
Prostate, Uterus, Head & Neck, Adenocarcinoma
ECM
GO-C15
Immunokine
Breast, Prostate, Bladder, Oral Squamous Cell Carcinoma, Head & Neck Squamous Cell Carcinoma, Colorectal, Lung
ANTIBODY PROGRAM
GO-C15
MODALITIES
Immunokine
INDICATIONS
Breast, Prostate, Bladder, Oral Squamous Cell Carcinoma, Head & Neck Squamous Cell Carcinoma, Colorectal, Lung
